公开(公告)号：US09814704B2

公开(公告)日：2017-11-14

申请号：US15172355

申请日：2016-06-03

Applicant: The University of Rochester

Inventor： Harris A. Gelbard ,  Stephen Dewhurst ,  Val S. Goodfellow ,  Colin J. Loweth ,  Torsten Wiemann

IPC: C07D471/04 ,  A61K31/437 ,  A61K45/06 ,  C07D487/04 ,  A61K31/438 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  C07D471/10 ,  A61K31/444

CPC classification number: A61K31/437 ,  A61K31/438 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  A61K2300/00

Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

公开(公告)号：US20160024087A1

公开(公告)日：2016-01-28

申请号：US14876345

申请日：2015-10-06

Applicant: The University of Rochester

Inventor： Harris A. Gelbard ,  Stephen Dewhurst ,  Val S. Goodfellow ,  Colin J. Loweth ,  Torsten Wiemann

IPC: C07D471/04 ,  A61K31/553 ,  A61K31/496 ,  A61K31/438 ,  C07D487/04 ,  A61K31/4985 ,  A61K31/5377 ,  C07D471/10 ,  A61K31/437 ,  A61K31/506

CPC classification number: A61K31/437 ,  A61K31/438 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  A61K2300/00

Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

公开(公告)号：US09181247B2

公开(公告)日：2015-11-10

申请号：US14508566

申请日：2014-10-07

Applicant: The University of Rochester

Inventor： Harris A. Gelbard ,  Stephen Dewhurst ,  Val S. Goodfellow ,  Colin J. Loweth ,  Torsten Wiemann

IPC: A61K31/437 ,  C07D471/04 ,  A61K45/06 ,  C07D487/04

CPC classification number: A61K31/437 ,  A61K31/438 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  A61K2300/00

Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo [2,3b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Abstract translation: 提供对混合谱系激酶具有抑制作用的化合物。 化合物包括具有式IX的取代的吡咯并[2,3b]吡啶。还提供了药物组合物，制备化合物的方法，合成中间体，以及独立地或与其它治疗剂组合使用化合物治疗疾病和病症的方法 其受到混合谱系激酶抑制的影响。 还提供了治疗包含抑制混合谱系激酶的神经精神障碍的方法。

公开(公告)号：US20160317509A1

公开(公告)日：2016-11-03

申请号：US15172355

申请日：2016-06-03

Applicant: The University of Rochester

Inventor： Harris A. Gelbard ,  Stephen Dewhurst ,  Val S. Goodfellow ,  Colin J. Loweth ,  Torsten Wiemann

IPC: A61K31/437 ,  A61K31/496 ,  A61K31/506 ,  A61K31/444

CPC classification number: A61K31/437 ,  A61K31/438 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/553 ,  A61K45/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  A61K2300/00

Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.